{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T23:47:06Z","timestamp":1768175226122,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12282-025-01778-4","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T21:32:08Z","timestamp":1758835928000},"page":"99-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathological homogeneity and utility in the genetic diagnosis of paired mirror samples from breast cancer 10G-vacuum-assisted biopsies using a novel longitudinal dividing device"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0496-5945","authenticated-orcid":false,"given":"Akira","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6896-3088","authenticated-orcid":false,"given":"Sae","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikage","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2663-0142","authenticated-orcid":false,"given":"Ryo","family":"Tsunashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chise","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saya","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikoi","family":"Omatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-652X","authenticated-orcid":false,"given":"Yoshiaki","family":"Sota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8529-8915","authenticated-orcid":false,"given":"Takumi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7443-2621","authenticated-orcid":false,"given":"Masayoshi","family":"Okumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4083-4432","authenticated-orcid":false,"given":"Midori","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3443-3210","authenticated-orcid":false,"given":"Osamu","family":"Ukimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-0137","authenticated-orcid":false,"given":"Yasuto","family":"Naoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"1778_CR1","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817\u201326.","journal-title":"N Engl J Med"},{"key":"1778_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111\u201321.","journal-title":"N Engl J Med"},{"key":"1778_CR3","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336\u201347.","journal-title":"N Engl J Med"},{"key":"1778_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, van\u2019t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717\u201329.","journal-title":"N Engl J Med"},{"key":"1778_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10549-010-1145-z","volume":"128","author":"N Yasuto","year":"2011","unstructured":"Yasuto N, Kazuki K, Tomonori T, Ryo T, Naomi T, Yosuka B, et al. Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients. Breast Cancer Res Treat. 2011;128:633\u201341.","journal-title":"Breast Cancer Res Treat"},{"key":"1778_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u201321.","journal-title":"N Engl J Med"},{"key":"1778_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25\u201332.","journal-title":"Lancet Oncol"},{"key":"1778_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.humpath.2010.08.026","volume":"43","author":"Y Choi","year":"2012","unstructured":"Choi Y, Kim EJ, Seol H, Lee HE, Jang MJ, Kim SM, et al. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal\/multicentric invasive ductal carcinoma of breast. Hum Pathol. 2012;43:48\u201355.","journal-title":"Hum Pathol"},{"key":"1778_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cncr.28375","volume":"120","author":"G Pekar","year":"2014","unstructured":"Pekar G, Gere M, Tarjan M, Hellberg D, Tot T. Molecular phenotype of the foci in multifocal invasive breast carcinomas: intertumoral heterogeneity is related to shorter survival and may influence the choice of therapy. Cancer. 2014;120:26\u201334.","journal-title":"Cancer"},{"key":"1778_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74136-3","volume":"10","author":"T Shiraishi","year":"2020","unstructured":"Shiraishi T, Inui S, Inoue Y, Saito Y, Taga H, Kaneko M, et al. Usefulness of a novel device to divide core needle biopsy specimens in a spatially matched fashion. Sci Rep. 2020;10:17098.","journal-title":"Sci Rep"},{"key":"1778_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33776-x","volume":"13","author":"Y Nakamura","year":"2023","unstructured":"Nakamura Y, Tsuji K, Shiraishi T, Sako S, Ogura R, Taga H, et al. Novel device for dividing core needle biopsy specimens to provide paired mirror image-like tissues for genetic and pathological tests. Sci Rep. 2023;13:6610.","journal-title":"Sci Rep"},{"key":"1778_CR12","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160\u20137.","journal-title":"J Clin Oncol"},{"key":"1778_CR13","first-page":"2680","volume":"42","author":"Y Naoi","year":"2019","unstructured":"Naoi Y, Saito Y, Kishi K, Shimoda M, Kagara N, Miyake T, et al. Development of recurrence risk score using 95-gene classifier and its application to formalin-fixed paraffin-embedded tissues in ER-positive, HER2-negative and node-negative breast cancer. Oncol Rep. 2019;42:2680\u20135.","journal-title":"Oncol Rep"},{"key":"1778_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.21873\/anticanres.16209","volume":"43","author":"H Yamashita","year":"2023","unstructured":"Yamashita H, Hatanaka KC, Yamagishi K, Saito Y, Hamasaki K, Taniguchi M, et al. Evaluation of 95-gene classifier of formalin-fixed paraffin-embedded tissues in ER-positive, HER2-negative, and node-negative breast cancer. Anticancer Res. 2023;43:707\u201311.","journal-title":"Anticancer Res"},{"key":"1778_CR15","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-11-0926","volume":"17","author":"M Filipits","year":"2011","unstructured":"Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17:6012\u201320.","journal-title":"Clin Cancer Res"},{"key":"1778_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s12282-024-01573-7","volume":"31","author":"A Watanabe","year":"2024","unstructured":"Watanabe A, Tsunashima R, Kato C, Kitano S, Matsumoto S, Sota Y, et al. Investigation of recurrence prediction ability of EndoPredict\u00ae using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict\u00ae from microarray data from fresh-frozen to FFPE tissues. Breast Cancer. 2024;31:593\u2013606.","journal-title":"Breast Cancer"},{"key":"1778_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s10549-011-1676-y","volume":"132","author":"B Gy\u0151rffy","year":"2012","unstructured":"Gy\u0151rffy B, Benke Z, L\u00e1nczky A, Bal\u00e1zs B, Sz\u00e1ll\u00e1si Z, Tim\u00e1r J, et al. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat. 2012;132:1025\u201334.","journal-title":"Breast Cancer Res Treat"},{"key":"1778_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4143\/crt.2018.342","volume":"51","author":"HK Kim","year":"2019","unstructured":"Kim HK, Park KH, Kim Y, Park SE, Lee HS, Lim SW, et al. Discordance of the PAM50 intrinsic subtypes compared with immunohistochemistry-based surrogate in breast cancer patients: potential implication of genomic alterations of discordance. Cancer Res Treat. 2019;51:737\u201347.","journal-title":"Cancer Res Treat"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01778-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-025-01778-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01778-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:05:26Z","timestamp":1768165526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-025-01778-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1778"],"URL":"https:\/\/doi.org\/10.1007\/s12282-025-01778-4","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasuto Naoi\u00a0has received research funding from\u00a0Sysmex,\u00a0ONO, Daiichi-Sankyo and AstraZeneca, and honoraria from AstraZeneca, Pfizer, Eli Lilly, ONO, Daiichi-Sankyo and Chugai outside the submitted work; he holds joint patents with Sysmex including Curebest\u2122 95GC Breast (JP.5725274.B2). Osamu Ukimura and Takumi Shiraishi are the patent inventor of the tissue-dividing device. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Kyoto Prefectural University of Medicine Ethics Committee (ERB-C-2415-1).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}